



Partnering with The Vaccine Fund

# Progress Report

to the  
Global Alliance for Vaccines and Immunization (GAVI)  
and  
The Vaccine Fund

by the Government of

|                            |
|----------------------------|
| <b>COUNTRY: Azerbaijan</b> |
|----------------------------|

Date of submission: ...01.10.03.....

Reporting period: 2002..... ( Information provided in this report **MUST** refer to the previous calendar year )

( Tick only one ) :

- Inception report
- First annual progress report
- Second annual progress report
- Third annual progress report
- Fourth annual progress report
- Fifth annual progress report

*Text boxes supplied in this report are meant only to be used as guides. Please feel free to add text beyond the space provided.*

**\*Unless otherwise specified, documents may be shared with the GAVI partners and collaborators**

*Signed copy  
+ ICC  
minuted*

June 2003

# Progress Report Form: Table of Contents

## 1. Report on progress made during the previous calendar year

- 1.1 Immunization Services Support (ISS)
  - 1.1.1 Management of ISS Funds
  - 1.1.2 Use of Immunization Services Support
  - 1.1.3 Immunization Data Quality Audit
- 1.2 GAVI/Vaccine Fund New and Under-used Vaccines
  - 1.2.1 Receipt of new and under-used vaccines
  - 1.2.2 Major activities
  - 1.2.3 Use if GAVI/The Vaccine Fund financial support (US\$100,000) for introduction of the new vaccine
- 1.3 Injection Safety
  - 1.3.1 Receipt of injection safety support
  - 1.3.2 Progress of transition plan for safe injections and safe management of sharps waste
  - 1.3.3 Statement on use of GAVI/The Vaccine Fund injection safety support (if received in the form of a cash contribution)

## 2. Financial Sustainability

## 3. Request for new and under-used vaccine for year... (indicate forthcoming year)

- 3.1 Up-dated immunization targets
- 3.2 Confirmed/revised request for new vaccine (to be shared with UNICEF Supply Division) for year...
- 3.3 Confirmed/revised request for injection safety support for the year...

## 4. Please report on progress since submission of the last Progress Report based on the indicators selected by your country in the proposal for GAVI/VF support

## 5. Checklist

## 6. Comments

## 7. Signatures

**1. Report on progress made during the previous calendar year**

To be filled in by the country for each type of support received from GAVI/The Vaccine Fund.

**1.1 Immunization Services Support (ISS)**

**1.1.1 Management of ISS Funds**

→ Please describe the mechanism for management of ISS funds, including the role of the Inter-Agency Co-ordinating Committee (ICC).  
Please report on any problems that have been encountered involving the use of those funds, such as delay in availability for programme use.

Management of ISS funds is carried out by Health Ministry, involving senior specialists. Then it is brought up to the discussion of Interagency Coordination Committee with the adoption of appropriate recommendations.  
The problem was arisen in the process of taking decision re the use of part of fund for the missing vaccines: DTP and DT not supplied on the line of UNICEF. During the discussion of this question on ICC, representatives of UNICEF pledged to supply missing vaccines (which was done) and ISS funds was applied on assignment.

**1.1.2 Use of Immunization Services Support**

→ In the past year, the following major areas of activities have been funded with the GAVI/Vaccine Fund contribution.

Funds received during the reporting year 16497\$, 99997\$  
Remaining funds (carry over) from the previous year 495\$

**Table 1 Use of funds during reported calendar year 2002**

| Area of Immunization Services Support | Total amount in US \$ | Amount of funds |   |          |                                       |
|---------------------------------------|-----------------------|-----------------|---|----------|---------------------------------------|
|                                       |                       | Central         | <del>PUBLIC SECTOR</del><br>Region/State/Province | District | <del>PRIVATE SECTOR &amp; Other</del> |
| Vaccines                              |                       |                 |   |          |                                       |
| Injection supplies                    | 57.335                | 57.335          |   |          |                                       |
| Personnel                             |                       |                 |   |          |                                       |
| Transportation                        |                       |                 |   |          |                                       |
| Maintenance and overheads             | 732                   | 732             |   |          |                                       |
| Training                              |                       |                 |   |          |                                       |
| IEC / social mobilization             |                       |                 |   |          |                                       |
| Outreach                              |                       |                 |   |          |                                       |
| Supervision                           |                       |                 |   |          |                                       |
| Monitoring and evaluation             |                       |                 |   |          |                                       |
| Epidemiological surveillance          | 8.383                 | 8.383           |   |          |                                       |
| Vehicles                              | 8.450                 | 8.450           |   |          |                                       |
| Cold chain equipment                  |                       |                 |   |          |                                       |
| Other ..... (specify)                 | 22.147                | 22.147          |   |          |                                       |
| <b>Total:</b>                         | <b>116.989</b>        | <b>116.989</b>  |   |          |                                       |
| <b>Remaining funds for next year:</b> |                       |                 |   |          |                                       |

*\*If no information is available because of block grants, please indicate under 'other'.*

*Please attach the minutes of the ICC meeting(s) when the allocation of funds was discussed.*

→ *Please report on major activities conducted to strengthen immunization, as well as, problems encountered in relation to your multi-year plan.*

*The programme for struggle against poverty for 2003-2007 was developed and the government undertook the financing from 2003 purchase of all vaccines except vaccines against Hepatitis B and MMR vaccines.  
 From 2003 new vaccine – MMR for vaccination of children of 12 month and 6 years of age provided by Vishnevskaya-Rostropovich Foundation was inserted to the vaccination calendar.*

**1.1.3 Immunization Data Quality Audit (DQA) (If it has been implemented in your country)**

→ *Has a plan of action to improve the reporting system based on the recommendations from the DQA been prepared?  
 If yes, please attach the plan.*

YES  NO

→ *If yes, please attach the plan and report on the degree of its implementation.*

*- New forms of birth and mortality registration was introduced.  
 - From second half of 2003 quarterly reporting form about the routine immunization coverage recommended by WHO was implemented everywhere, that will be monthly submitted by regions from 01.01.2004.*

*Please attach the minutes of the ICC meeting where the plan of action for the DOA was discussed and endorsed by the ICC.*

→ *Please list studies conducted regarding EPI issues during the last year (for example, coverage surveys, cold chain assessment, EPI review).*

*Monitoring of cold chain carried out in 2001 with support of UNICEF, and in 2002 with support of GAVI in 54 districts and regions had the following results: cold storages of Centre's of Hygiene and Epidemiology are fully provided with cold equipments (on line of UNICEF), refrigerators and freezers are high quality with their technical parameters and they provide required temperature regime and safe keeping of bacteriological preparations provided that secure power provision. In vaccination rooms of medical facilities of different level 70% of refrigerators were morally and physically time-*

worn, their exploitation life was over 15 years. Health reforms and support from GAVI and State Budget allowed to renew 5% of cold chain equipments. Over 50% of medical facilities are in need for thermo-bags. By the decision of ICC part of the fund was directed to the support of cold chain.

**1.2 GAVI/Vaccine Fund New & Under-used Vaccines Support**

**1.2.1 Receipt of new and under-used vaccines during the previous calendar year**

→ Please report on receipt of vaccines provided by GAVI/VF, including problems encountered.

In 2002, 280.000 vaccines were received.  
There was not problems with receipt (deliver) and distribution of vaccines from GAVI.

**1.2.2 Major activities**

→ Please outline major activities that have been or will be undertaken, in relation to, introduction, phasing-in, service strengthening, etc. and report on problems encountered.

Deliver of 30% 2-doses Hepatitis B vaccines from all applied quantity allowed to decrease wastage by 50%. 2-doses vaccines were provided for sparsely populated stations.

**1.2.3 Use of GAVI/The Vaccine Fund financial support (US\$100,000) for the introduction of the new vaccine**

→ Please report on the proportion of 100,000 US\$ used, activities undertaken, and problems encountered such as delay in availability of funds for programme use.

- 1) Syringes: BCG - 57335 \$
- 2) Cold chain equipments: refrigerators – 3.621\$  
Generators – 2.615\$
- 3) aggregate for destruction of contaminated materials – 10 ones – 22.147\$
- 4) vehicle (cross country vehicle) – 8450 \$
- 5) monitoring of cold chain in 24 regions – 5.100\$

**1.3 Injection Safety**

**1.3.1 Receipt of injection safety support**

→ Please report on receipt of injection safety support provided by GAVI/IF, including problems encountered

- Purchased: self-destroyable syringes - 500.000 ones
- Aggregates for destruction of used injective materials – 10 ones

**1.3.2 Progress of transition plan for safe injections and safe management of sharps waste.**

→ Please report on the progress based on the indicators chosen by your country in the proposal for GAVI/IF support.

| Indicators   | Targets | Achievements | Constraints | Updated targets |
|--|---------|--------------|-------------|-----------------|
| 1) Provision of self destroyable syringes                              | 100%    |              |             | By year of 2013 |
| 2) availability of containers for collecting used syringes             | 100%    |              |             |                 |
| 3) availability of system for destruction of used syringes and needles | 100%    |              |             |                 |

|                                       |      |  |  |                 |
|---------------------------------------|------|--|--|-----------------|
| 4) provision of cold chain equipments | 100% |  |  | By year of 2013 |
|---------------------------------------|------|--|--|-----------------|

**1.3.3 Statement on use of GAVI/The Vaccine Fund injection safety support (if received in the form of a cash contribution)**

→ The following major areas of activities have been funded (specify the amount) with the GAVI/The Vaccine Fund injection safety support in the past year:

- 1) Training of medical personnel in relation with introduction of Hepatitis B vaccine
- 2) Strengthening of cold chain
- 3) Progress monitoring of Expanded Immunization Programme (in 2003)

**2. Financial sustainability**

**Inception Report :** Outline timetable and major steps taken towards improving financial sustainability and the development of a financial sustainability plan.

**First Annual Report :** Report progress on steps taken and update timetable for improving financial sustainability  
Submit completed financial sustainability plan by given deadline and describe assistance that will be needed for financial sustainability planning.

**Second Annual Progress Report :** Append financial sustainability action plan and describe any progress to date.  
 Describe indicators selected for monitoring financial sustainability plans and include baseline and current values for each indicator.

**Subsequent reports:** Summarize progress made against the FSP strategic plan. Describe successes, difficulties and how challenges encountered were addressed. Include future planned action steps, their timing and persons responsible.  
 Report current values for indicators selected to monitor progress towards financial sustainability. Describe the reasons for the evolution of these indicators in relation to the baseline and previous year values.  
 Update the estimates on program costs and financing with a focus on the last year, the current year and the next 3 years. For the last year and current year, update the estimates of expected funding provided in the FSP tables with actual funds received since. For the next 3 years, update any changes in the costing and financing projections. The updates should be reported using the same standardized tables and tools



used for the development of the FSP (latest versions available on <http://www.gaviff.org> under FSP guidelines and annexes).

Highlight assistance needed from partners at local, regional and/or global level

Sustainable financial plan of immunization programme is on the process of development.  
 Sections 3 and 4 are prepared and now on the consideration of Ministry of Finance  
 Course of sustainable financing plan was discussed in the meeting of ICC

**3. Request for new and under-used vaccines for year 2002. (indicate forthcoming year.)**

*Section 3 is related to the request for new and under used vaccines and injection safety for the forthcoming year.*

**3.1. Up-dated immunization targets**

Confirm/update basic data (= surviving infants, DTP3 targets, New vaccination targets) approved with country application: revised Table 4 of approved application form.

DTP3 reported figures are expected to be consistent with those reported in the WHO/UNICEF Joint Reporting Forms. Any changes and/or discrepancies **MUST** be justified in the space provided (page 10) . Targets for future years **MUST** be provided.

**Table 2 : Baseline and annual targets**

| Number of           | Baseline and targets |         |         |         |         |         |         |         |
|---------------------|----------------------|---------|---------|---------|---------|---------|---------|---------|
|                     | 2000                 | 2001    | 2002    | 2003    | 2004    | 2005    | 2006    | 2007    |
| <b>DENOMINATORS</b> |                      |         |         |         |         |         |         |         |
| Births              | 116.994              | 110.356 | 110.715 | 113.898 | 115.103 | 116.035 | 116.975 | 117.922 |
| Infants' deaths     | 3306                 | 3270    | 3292    | 3324    | 3.361   | 3.388   | 3.416   | 3.443   |
| Surviving infants   | 113.688              | 107.086 | 107.423 | 110.565 | 111.742 | 112.647 | 113.559 | 114.479 |

|   |         |         |         |               |         |         |         |         |
|---|---------|---------|---------|---------------|---------|---------|---------|---------|
| <b>Infants vaccinated with DTP3 *</b>   |         |         |         |               |         |         |         |         |
| Infants vaccinated with DTP3: administrative figure reported in the WHO/UNICEF Joint Reporting Form | 103.038 | 97.702  | 93.421  | 93.980        | 98.333  | 101.382 | 104.475 | 106.466 |
| <b>NEW VACCINES</b>   |         |         |         |               |         |         |         |         |
| Infants vaccinated with _____ * (use one row per new vaccine)                                       |         | 22.345  | 93.223  | 96.000        | 100.568 | 103.635 | 104.475 | 106.466 |
| Wastage rate of ** ..... (new vaccine)  |         | 25%     | 25%     | 25%           | 25%     | 25%     | 25%     | 20%     |
| <b>INJECTION SAFETY</b>   |         |         |         |               |         |         |         |         |
| <b>Pregnant women vaccinated with TT</b>  |         |         |         |               |         |         |         |         |
| Infants vaccinated with BCG   | 114.537 | 108.700 | 107.390 | 111.620       | 100.568 | 103.635 | 105.610 | 107.610 |
| Infants vaccinated with Measles   | 112.324 | 105.908 | 103.112 | 75% - measles |         |         |         |         |
| Infants vaccinated with MMR   |         |         |         | 25% - MMR     | 100.568 | 101.382 | 104.475 | 105.321 |


\* Indicate actual number of children vaccinated in past years and updated targets

\*\* Indicate actual wastage rate obtained in past years

→ Please provide justification on changes to baseline, targets, wastage rate, vaccine presentation, etc. from the previously approved plan, and on reported figures which differ from those reported in the WHO/UNICEF Joint Reporting Form in the space provided below.

*IN the process of sustainable financial plan development demographic figures were corrected based on the data from Sate Statistical Committee.*

3.2 Confirmed/Revised request for new vaccine (to be shared with UNICEF Supply Division) for the year ... (indicate forthcoming year)



Please indicate that UNICEF Supply Division has assured the availability of the new quantity of supply according to new changes.

Table 3: Estimated number of doses of *Hepatitis B* vaccine (specify for one presentation only) : (Please repeat this table for any other vaccine presentation requested from GAVI/The Vaccine Fund

|          | Formula  | For year 2004                                |
|----------|--|--|
| <b>A</b> | Number of children to receive new vaccine  | * 115.103                                    |
| <b>B</b> | Percentage of vaccines requested from The Vaccine Fund taking into consideration the Financial Sustainability Plan | % 100%                                       |
| <b>C</b> | Number of doses per child  | 3  |
| <b>D</b> | Number of doses  | $A \times B / 100 \times C$ 345.309          |
| <b>E</b> | Estimated wastage factor   | (see list in table 3) 1.33                   |
| <b>F</b> | Number of doses (incl. wastage)  | $A \times C \times E \times B / 100$ 459.261 |
| <b>G</b> | Vaccines buffer stock  | $F \times 0.25$ 0                            |
| <b>H</b> | Anticipated vaccines in stock at start of year ....  | 0  |
| <b>I</b> | Total vaccine doses requested  | $F + G - H$ 459.261                          |

**Remarks**

**Phasing:** Please adjust estimates of target number of children to receive new vaccines, if a phased introduction is intended. If targets for hep B3 and Hib3 differ from DTP3, explanation of the difference should be provided

**Wastage of vaccines:** The country would aim for a maximum wastage rate of 25% for the first year with a plan to gradually reduce it to 15% by the third year. No maximum limits have been set for yellow fever vaccine in multi-dose vials.

**Buffer stock:** The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero under other years. In case of a phased introduction with the buffer stock spread over several years, the formula should read: [ F – number of doses (incl. wastage) received in previous year ] \* 0.25.

**Anticipated vaccines in stock at start of year... ..:** It is calculated by deducting the buffer stock received in previous years from the current balance of vaccines in stock.

**AD syringes:** A wastage factor of 1.11 is applied to the total number of vaccine doses requested from the Fund, including the wastage of syringes.

|          |  |                             |                  |
|----------|--|-----------------------------|------------------|
| <b>J</b> | <b>Number of doses per vial</b>                    | 2-doses<br>10-doses         | 68.890<br>32.149 |
| <b>K</b> | <b>Number of AD syringes (+ 10% wastage)</b>       | $(D + G - H) \times 1.11$   | 383.293          |
| <b>L</b> | <b>Reconstitution syringes (+ 10% wastage)</b>     | $1/J \times 1.11$           | 0                |
| <b>M</b> | <b>Total of safety boxes (+ 10% of extra need)</b> | $(K + L) / 100 \times 1.11$ | 4.255            |

doses requested from the Fund, excluding the wastage of vaccines.

**Reconstitution syringes:** it applies only for lyophilized vaccines. Write zero for other vaccines.

**Safety boxes:** A multiplying factor of 1.11 is applied to safety boxes to cater for areas where one box will be used for less than 100 syringes

**Table 3 : Wastage rates and factors**

|                           |      |      |      |      |      |      |      |      |      |      |      |      |
|---------------------------|------|------|------|------|------|------|------|------|------|------|------|------|
| Vaccine wastage rate      | 5%   | 10%  | 15%  | 20%  | 25%  | 30%  | 35%  | 40%  | 45%  | 50%  | 55%  | 60%  |
| Equivalent wastage factor | 1.05 | 1.11 | 1.18 | 1.25 | 1.33 | 1.43 | 1.54 | 1.67 | 1.82 | 2.00 | 2.22 | 2.50 |

*\*Please report the same figure as in table 1.*

### 3.3 Confirmed/revised request for injection safety support for the year ..... (indicate forthcoming year)

**Table 4: Estimated supplies for safety of vaccination for the next two years with ..... (Use one table for each vaccine BCG, DTP, measles and TT, and number them from 4 to 8)**

|          |   | <b>Formula</b> | <b>For year 2004</b> | <b>For year 2005</b> |
|----------|---|----------------|----------------------|----------------------|
| <b>A</b> | <b>Target of children for MMR vaccination (for TT : target of pregnant women)<sup>1</sup></b> | #              | 111.742              | 112.647              |
| <b>B</b> | <b>Number of doses per child (for TT woman)</b>   | #              | 1                    | 1                    |
| <b>C</b> | <b>Number of ..... doses</b>  | A x B          | 111.742              | 112.647              |
| <b>D</b> | <b>AD syringes (+10% wastage)</b>   | C x 1.11       | 124.033              | 125.038              |

<sup>1</sup> GAVI will fund the procurement of AD syringes to deliver 2 doses of TT to pregnant women. If the immunization policy of the country includes all Women of Child Bearing Age (WCBA), GAVI/The Vaccine Fund will contribute to a maximum of 2 doses for Pregnant Women (estimated as total births).

|   |   |                              |                      |                      |
|---|---|------------------------------|----------------------|----------------------|
| E | AD syringes buffer stock <sup>2</sup>   | $D \times 0.25$              | 0                    | 0                    |
| F | Total AD syringes   | $D + E$                      | 124.033              | 125.038              |
| G | Number of doses per vial  |                              | 12.403               | 12.503               |
| H | Vaccine wastage factor <sup>4</sup>   | <i>Either 2 or 1.6</i>       | 1.6                  | 1.6                  |
| I | Number of reconstitution <sup>3</sup> syringes (+10% wastage)                           | $C \times H \times 1.11 / G$ | 19.845               | 20.006               |
| J | Number of safety boxes (+10% of extra need)   | $(F + I) \times 1.11 / 100$  |                      | 1610                 |
|   |   | <b>Formula</b>               | <b>For year 2004</b> | <b>For year 2005</b> |
| A | Target of children for BCG vaccination (for TT : target of pregnant women) <sup>4</sup> | #                            | 115.103              | 116.035              |
| B | Number of doses per child (for TT woman)  | #                            | 1                    |                      |
| C | Number of ..... doses   | $A \times B$                 |                      |                      |
| D | AD syringes (+10% wastage)  |                              |                      |                      |

<sup>2</sup> The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero for other years.

<sup>3</sup> Only for lyophilized vaccines. Write zero for other vaccines

<sup>4</sup> Standard wastage factor will be used for calculation of re-constitution syringes. It will be 2 for BCG, 1.6 for measles and YF.

<sup>4</sup> GAVI will fund the procurement of AD syringes to deliver 2 doses of TT to pregnant women. If the immunization policy of the country includes all Women of Child Bearing Age (WCBA), GAVI/The Vaccine Fund will contribute to a maximum of 2 doses for Pregnant Women (estimated as total births).

|   |   |                      |               |               |
|---|---|----------------------|---------------|---------------|
| E | AD syringes buffer stock <sup>5</sup>   | D x 0.25             | 0             | 0             |
| F | Total AD syringes   |                      | 127.765       |               |
|   | Number of doses per vial  |                      | 12.776        | 12.879        |
|   | Vaccine wastage factor <sup>4</sup>   | Either 2 or 1.6      | 2             | 2             |
| I | Number of reconstitution <sup>6</sup> syringes (+10% wastage)                           | C x H x 1.11 / G     | 25.553        | 28.594        |
| J | Number of safety boxes (+10% of extra need)   | (F + I) x 1.11 / 100 | 1702          | 1747          |
|   |   | Formula              | For year 2004 | For year 2005 |
| A | Target of children for DTP vaccination (for TT : target of pregnant women) <sup>7</sup> | #                    | 115.103       | 116.035       |
| B | Number of doses per child (for TT woman)  | #                    | 3             | 3             |
| C | Number of ..... doses   | A x B                | 345.309       | 348.105       |
| D | AD syringes (+10% wastage)  | C x 1.11             | 383.243       | 386.396       |
| E | AD syringes buffer stock <sup>8</sup>   | D x 0.25             | 0             | 0             |
| F | Total AD syringes   | D + E                | 383.293       | 386.396       |
| G | Number of doses per vial  | 10- doses            | 38.329        | 38.639        |
| H | Vaccine wastage factor <sup>4</sup>   | Either 2 or 1.6      | 1.6           | 1.6           |
| I | Number of reconstitution <sup>9</sup> syringes (+10% wastage)                           | C x H x 1.11 / G     | 61.327        | 61.823        |
|   | Number of safety boxes (+10% of extra need)   | (F + I) x 1.11 / 100 | 4.935         | 4.975         |

**Table 5: Summary of total supplies for safety of vaccinations with BCG, DTP, TT and measles for the next two years.**

| ITEM              |         | For the year 2004 | For the year 2005 | Justification of changes from originally approved supply: |
|-------------------|---------|-------------------|-------------------|---|
| Total AD syringes | for BCG | 122.765           | 128.799           |   |

<sup>5</sup> The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero for other years.

<sup>6</sup> Only for lyophilized vaccines. Write zero for other vaccines

<sup>4</sup> Standard wastage factor will be used for calculation of re-constitution syringes. It will be 2 for BCG, 1.6 for measles and YF.

<sup>7</sup> GAVI will fund the procurement of AD syringes to deliver 2 doses of TT to pregnant women. If the immunization policy of the country includes all Women of Child Bearing Age (WCBA), GAVI/The Vaccine Fund will contribute to a maximum of 2 doses for Pregnant Women (estimated as total births).

<sup>8</sup> The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area. Write zero for other years.

<sup>9</sup> Only for lyophilized vaccines. Write zero for other vaccines

<sup>4</sup> Standard wastage factor will be used for calculation of re-constitution syringes. It will be 2 for BCG, 1.6 for measles and YF.

|                                  |                    |           |           |
|----------------------------------|--------------------|-----------|-----------|
|                                  | for other vaccines | 890.619   | 897.830   |
| Total of reconstitution syringes |                    | 1.018.384 | 1.026.629 |
| Total of safety boxes            |                    | 12.489    | 13.307    |

→ If quantity of current request differs from the GAVI letter of approval, please present the justification for that difference.

**4. Please report on progress since submission of the last Progress Report based on the indicators selected by your country in the proposal for GAVI/VE support**

| Indicators | Targets | Achievements | Constraints | Updated targets |
|------------|---------|--------------|-------------|-----------------|
|------------|---------|--------------|-------------|-----------------|

Since the indicators were included to the EIP only in 2002 there is not possibility to talk about the progress. We will talk about that in 2003.

In 2002, 670 medical personnel were trained in relation with introduction of Hepatitis B vaccine. Monitoring of cold chain was carried out in 45% of all districts. Provision with containers for collection of used injection materials was 100%. IN 70% of districts in the republic debugged system for destruction of used injection materials is functioning.

**5. Checklist**

Checklist of completed form:

| Form Requirement:   | Completed | Comments |
|---|-----------|----------|
| Date of submission  |           |          |
| Reporting Period (consistent with previous calendar year) |           |          |
| Table 1 filled-in   |           |          |
| DQA reported on   |           |          |





|   |  |  |
|---|--|--|
| Reported on use of 100,000 US\$                                   |  |  |
| Injection Safety Reported on                                      |  |  |
| FSP Reported on (progress against country FSP indicators)         |  |  |
| Table 2 filled-in   |  |  |
| New Vaccine Request completed                                     |  |  |
| Revised request for injection safety completed (where applicable) |  |  |
| ICC minutes attached to the report                                |  |  |
| Government signatures   |  |  |
| ICC endorsed  |  |  |

**6. Comments**

→ *ICC comments:*

\_\_\_\_\_

**7. Signatures**

For the Government of Azerbaijan, Dr Abbas Valibayov...

Signature:

Title: Deputy

Date: 01.10.2003.



We, the undersigned members of the Inter-Agency Co-ordinating Committee endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Financial accountability forms an integral part of GAVI/The Vaccine Fund monitoring of reporting of country performance. It is based on the regular government audit requirements as detailed in the Banking form. The ICC Members confirm that the funds received have been audited and accounted for according to standard government or partner requirements.

| Agency/Organisation | Name/Title | Date | Signature | Agency/Organisation | Name/Title | Date | Signature |
|---------------------|------------|------|-----------|---------------------|------------|------|-----------|
|                     |            |      |           |                     |            |      |           |
|                     |            |      |           |                     |            |      |           |
|                     |            |      |           |                     |            |      |           |
|                     |            |      |           |                     |            |      |           |
|                     |            |      |           |                     |            |      |           |
|                     |            |      |           |                     |            |      |           |
|                     |            |      |           |                     |            |      |           |

~ End ~